Top news of the week: 27.01.2023.
Aston University collaborates with biotechnology start-up to develop drugs to tackle lung disease
Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease. The ...
Top 100 Companies to Watch for Remote Jobs in 2023
FlexJobs, the leading career service specializing in remote and flexible jobs, today releases its 10th annual list of the Top 100 Companies to Watch for Remote Jobs in 2023. The list is ...
Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
Pulmobiotic is a spin off company from the Centre for Genomic Regulation (Barcelona - Spain) founded by experienced entrepreneurs and funded by invivo Ventures. Pulmobiotics will use its ...
Weekly Pharma & Life Science News Round-Up: 23rd – 27th January 2023
A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 23rd – 27th ...
Profluent debuts to design proteins with machine learning in bid to move past 'AI sprinkled on top'
While OpenAI's Microsoft-allied ChatGPT takes the world by storm, a fledgling startup in Berkeley, CA is debuting to take a similar language-learning model approach, but with the goal of ...
How small can you ‘omic? New startup wants to profile the tiny space between neurons to study Alzheimer’s
Single cell omic startups have popped up left and right, promising to improve drug discovery by processing large amounts of data from analyzing cells one at a time. But in a recent study ...
Bayer’s Marianne De Backer tasked with replacing George Scangos at Vir
After a career that has seen him lead Exelixis (Nasdaq: EXEL), Biogen (Nasdaq: BIIB) and most recently, Vir Biotechnology (Nasdaq: VIR), George Scangos is to retire in early …
EMA reviews first schistosomiasis drug for young children
The European Medicines Agency has validated a regulatory submission for arpraziquantel, a potential new treatment for schistosomiasis in young children.